Generic Name and Formulations:
Crisaborole 2%; oint.
Anacor Pharmaceuticals, Inc.
Indications for EUCRISA:
Mild-to-moderate atopic dermatitis.
Adults and Children:
<2yrs: not established. ≥2yrs: apply a thin layer twice daily to affected areas.
Not for ophthalmic, oral, intravaginal use. Discontinue immediately if hypersensitivity occurs. Pregnancy. Nursing mothers.
Phosphodiesterase 4 (PDE4) inhibitor.
Application site pain (eg, burning, stinging); hypersensitivity reactions, contact urticaria.
Clinical Pain Advisor Articles
- Aetna-CVS Merger Approved
- Striking a Balance Between Opioid Surveillance and Patient Privacy
- Demographic Characteristics of Pregnant Women With Opioid Use Disorder
- Effects of Mindfulness Therapy, Pharmacologic Prophylaxis on Catecholamine Levels in Migraine
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- Perioperative Pain Management in Patients With Opioid Use Disorder
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Managing Comorbid Opioid and Alcohol Use Disorder
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- Reviewing the Efficacy of Invasive Procedures for Chronic Back, Knee Pain
- What Do Clinicians Do in Response to Aberrant Urine Drug Test Results?
- Photo Elicitation on Social Media Can Provide Perspective to Patients With Chronic Pain
- Patients Assume Postoperative Opioids Are Best for Pain Relief
- Educational Disabilities More Likely With Neonatal Abstinence Syndrome
- When Will Medicine Join the Women's Movement?